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Western blotA B S T R A C T
Tuberculous meningitis (TBM) is a serious form of disease of the central nervous system.
Early and accurate diagnosis of the disease and effective treatment are key important fac-
tors to contain the disease. The disease presents as chronic meningitis where other part-
ners such as fungal meningitis, neurosyphilis, cysticercal meningitis, carcinomatous
meningitis and partially treated pyogenic meningitis share a similar clinical picture making
the diagnosis complicated. Culturing of the pathogen Mycobacterium tuberculosis (MTB)
from the cerebrospinal fluid (CSF) sample has shown a poor response. The main immuno-
logical method for the immunodiagnosis of TBM is the detection of an antibody response in
the CSF. In the present study, total MTB sonicated extract antigen was used for ELISA and
Western blot. ELISA shows overall immune response of the test sample, whereas Western
blotting reveals the specific reactivity to a particular molecular weight antigen. This would
also reveal the immunodominant antigen. A total of 300 CSF samples were analyzed by
both ELISA and Western blotting. Of the 240 clinically suspected TBM cases, 111 samples
were positive by ELISA and 81 samples byWestern blot. A total of 76 CSF samples were posi-
tive by both ELISA and Western blot. None of the control samples showed positivity either
by ELISA or by Western blot. TBM patients revealed major antibody reactivity to 30–40 kD
region, followed by 14 kD region. ELISA is sensitive with mild non-specific binding, but Wes-
tern blot is specific in detecting the immune response. The findings will be useful in defini-
tive immunodiagnosis of TBM.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB) is the leading cause of death among com-
municable diseases, killing nearly 1.4 million people eachyear [1]. The clinical presentation of TB ranges from a few foci
affecting the upper parts of the lungs to an intense tissue
destruction and caseous necrosis that usually disintegrates
forming cavity lesions, leading to bacteremia and further toin–Jensen;
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condition. Major forms of the CNS-TB are tuberculous menin-
gitis (TBM), intra-cranial tuberculomas and spinal tubercu-
lous arachnoiditis [2]. The disease carries a high mortality
rate and a distressing level of neurological morbidity. It
majorly affects immunocompromised individuals like chil-
dren and HIV-infected patients, subjects with malnutrition,
recent measles-infected children, alcoholics, subjects with
malignancies and immunosuppressive drug users [1,3]. A
high rate of mortality and/or morbidity in TBM is due to mis-
diagnosis or late diagnosis and lack of adequate and appropri-
ate treatment [4]. Clinically, TBM is presented with ill health
lasting 2–8 weeks prior to the development of meningeal irri-
tation. The classic presentations in adults are mild fever,
headache and neck stiffness along with focal neurological
deficits, behavioral changes and alterations in consciousness,
nausea and vomiting from moderate to more severe.
Improper treatment leads to lethargy and agitation and the
patient may end up in a coma [5–8]. Due to its being a rela-
tively rare condition and the protean nature of the symptoms,
CNS-TB remains a formidable diagnostic challenge to both
clinicians and laboratory scientists. In all forms of CNS-TB,
brain damage is reported to be from an immune-mediated
inflammatory response, which causes vasculitis, obstructive
hydrocephalus and cranial nerve palsy [9,10]. The close
differential diagnosis can be partially treated pyogenic
meningitis, fungal meningitis and at times carcinomatous
meningitis. In the case of TBM, CSF values become more
abnormal over time, with increasing leukocyte counts and
protein levels and decreasing glucose levels [11].
Microbiological detection of MTB in CSF by acid-fast staining
(Ziehl-Neelsen) and culturing is very poor. CSF culture
sensitivity reported is only up to 15–20% [12,13], although a
marginal increase in positivity is noticed with a high volume
of CSF samples. Recently, different types of liquid culture
isolation techniques are also in use for the rapid diagnosis
of TBM, apart from Lowenstein–Jensen (LJ) medium, the con-
ventional solid medium.
To overcome the diagnostic lacunae, a number of immuno-
logical and molecular methods have been explored. The
nucleic acid amplification tests developed for the diagnosis
of the disease were also not fully satisfactory due to the fact
that there is less bacterial load in CSF samples [14,15].
Another novel diagnostic method such as CSF interferon-
gamma release assay by the mycobacterial antigen stim-
ulation is being used as a biomarker in the diagnosis.
However, this test requires further evaluation and validation
to establish its utility as a diagnostic tool [16].
In view of the limitations of the above techniques, re-
evaluation of immunodiagnostic methods was considered.
Efforts were made to detect specific antibodies in CSF, which
can act as potential immune markers for the diagnosis of
TBM. Detection of mycobacterial antigens or antibodies in
the CSF is specific, simple, inexpensive, and requires minimal
training compared with other methods. The antibody-based
ELISA technique has been employed over the period for the
diagnosis of TBM [17]. A series of different antigens were also
used for TBM diagnosis, such as lipoarabinomannan, early
secretory antigen 6 (ESAT-6), A-60, Ag-5, 14 kD and MTB cul-
ture filtrate antigens [18–20]. However, all reports have a widerange of sensitivity and specificity. In an attempt to improve
the sensitivity of the CSF ELISA for the immunodiagnosis of
TBM, in the present study a total mixture of sonicated anti-
gens of MTB are being used. Further, for confirmation of the
immune response, Western blotting is performed to analyze




A total of 300 CSF samples were analyzed in the present study
by ELISA and Western blotting. Informed consent was
obtained from subjects before CSF was collected by lumbar
puncture. Institutional ethical approval was sought for the
study. Of the 300 CSF samples, 240 belonged to chronic
meningitis categories which were suspected for TBM.
Non-tuberculous cases (n = 30) involved Pyogenic meningitis,
Cryptococcal meningitis, Neurocysticercosis and Viral
meningoencephalitis. Non-diseased controls (n = 30) involved
subjects undergoing spinal anesthesia for non-neurological
causes. The inclusion and exclusion of subject selection were
followed as per the criteria of Marais et al. [21].
Suspected TBM CSF samples (n = 240)
Patients with clinical signs and symptoms of meningitis
including one or more of the following presentations like
headache, irritability, vomiting, fever, neck stiffness, convul-
sions, focal deficits, altered consciousness over a period of
one week and with typical radiological images showing
meningeal involvement and/or CSF culture positive for AFB
were classified as TBM cases.
In the present study, the initial presentation of cases is
shown in Table 1. Patients were classified as ‘highly proba-
ble’ TBM, ‘probable’ TBM, ‘possible’ TBM and non-TBM.
Confirmed TBM is based on a clinical presentation with
bacterial isolation from CSF. In the present study, highly
probable, probable and possible TBM are altogether
grouped as suspected TBM for Western blot. The criteria
followed for highly probable TBM (n = 53) are clinical
diagnosis as TBM, radiological impression as TBM and/or
CSF antibody positive by ELISA. Probable TBM (n = 85) is
considered when clinical diagnosis presents as TBM,
and doubtful radiological impression for TBM/antibody
positivity by ELISA. Possible TBM (n = 102) is clinical
suspicion of TBM or radiological impression of TBM or
antibody positivity by ELISA.
Non-tuberculous meningitis controls (n = 30)
Cases in which an alternative diagnosis is establishedwithout
a definitive diagnosis of TBM with convincing signs of other
disease were categorized as non-tuberculous meningitis
cases. Thirty CSF samples were taken as non-tuberculous
meningitis cases which included cases with Pyogenic
meningitis which were confirmed by isolation of Diplococcus
pneumonia, Cryptococcal meningitis cases confirmed by
isolation of Cryptococcus neoformans, and Neurocysticercosis
cases confirmed by anticysticercal antibody in the CSF against
Taenia solium cyst antigen. Viral meningitis cases were
Table 1 – Clinical presentation of 240 cases suspected for
tuberculous meningitis.
Clinical presentation Percentage of patients
Headache, vomiting and fever 33.3
Headache and vomiting 22.2
Vomiting 44.4
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positive by PCR.
Non-infectious diseased controls (n = 30)
Subjects undergoing spinal anesthesia for non-neurological
causes like hernia, hydrocele, etc., served as non-diseased
controls.
Other materials
MTB (H37Ra) culture, sonicator, other common laboratory
reagents, apparatus for Western blot, and ELISA were the
other materials used.
Preparation of antigen
MTB (H37Ra) was a kind gift from the National Referral
Laboratory JALMA, Agra (India). The organism was grown on
LJ media. Later the culture was transferred to 250 ml
Sauton’s liquid media and incubated at 37 C with gentle agi-
tation for 6 weeks. The above culture was centrifuged at
10,000 rpm at 4 C for 30 min to separate culture filtrate. The
pellet was inactivated by 5% phenol solution for one hour
and re-pelleted. The pellet was re-suspended in PBS, and
the suspension was sonicated in an ice bath for 15 min
(Sonics vibra cells, U.S.A), followed by centrifugation to get
clear sonicated supernatant rich in protein. The protein con-
tent was measured/adjusted and used for ELISA and Western
blotting.
Indirect ELISA
ELISA was done according to the method described earlier
[17]. Briefly, 96 well microtitre plates (Dynatech, U.S.A) were
coated with MTB sonicated extract (MTSE) antigen (10 lg/
mL) in PBS, 50 ll per well, by overnight incubation at 4 C in
a moist chamber. Unbound antigen was removed by washing
with PBST. Nonspecific free binding sites of the wells were
blocked with freshly prepared PBST-milk 1% at 37 C for 2 h.
After incubation, the plates were tap dried and stored at
20 C in dry condition until further use. The CSF samples
to be tested were diluted (1:10) in PBST milk 1% and 50 ll of
the diluted samples were added to the wells in duplicates.
The plate was incubated for 90 min in a moist chamber at
37 C and then washed with PBST ·5 and tap dried; 50 ll of
secondary antibody (anti-human IgG, Dakopatts, Denmark)
conjugated with HRP (1:3000 dilutions in PBST-milk) was
added to each well and incubated at 37 C for 60 min. The
plates were later washed with PBST and tap dried. Substrate(O-phenylene di-amine dissolved in phosphate citrate buffer
with hydrogen peroxide) was added to each well (75 ll) and
allowed for color development for 10–15 min. The reaction
was arrested by adding 50 ll of 2N H2SO4. The readings were
taken by ELISA reader (Sunrise-Magellan, Tecan AG, Austria)
at 492 nm. The cutoff value was calculated on the basis of
the absorbance (OD) value of controls (n = 60) by taking mean
of it plus three standard deviations (SD).
Western blot
The antigens of MTB sonicated extract (MTSE) were subjected
to SDS–PAGE. The antigens were first separated on
polyacrylamide gel (12%) in 0.1% SDS, along with the protein
marker with constant voltage in a discontinuous buffer
system using Hoeffer electrophoresis apparatus (U.S.A.). The
antigens thus separated were transferred to the nitrocellulose
membrane (0.45 lm pore size, MDI, Ambala, India) by electro
blotting (Hoeffer, U.S.A.). The blotted nitrocellulose
membrane having MTSE antigen was cut into fine strips of
3 mm breadth (8–10 lg of MTSE/strip) and stored at 20 C
until further use.
The strips werewashedwith distilled water before use and
later incubated with CSF diluted in 1% PBST milk (1:10) at
room temperature with gentle overnight shaking. After wash-
ing for 5 times with tris-buffered saline (TBS), the strips were
incubated with goat anti-human IgG immunoglobulin tagged
HRP (Dakopatts, Denmark, 1:1000 in PBST milk) for 3 h at
room temperature. After incubation, the strips were washed
5 times with TBS and were then developed with substrate
(4-chloronaphthol) and later stored in distilled water.
Immune reactivity to MTB antigenswas also checked by using
monoclonal antibodies obtained from Dr. J. Ivanyi, Wellcome
Laboratories (UK).Results
Anti-mycobacterial antibodies were detected by both ELISA
and Western blotting. The cutoff value for ELISA (mean + 3
SD of controls) was around 0.200 OD. Hence, samples showing
ODP 0.200 were taken as positive by ELISA. Samples showing
OD between 0.100 and 0.200 were taken as borderline positive
(taken as antibody positive for the analysis) and OD < 0.100
was taken as negative by the assay. Among the 240 suspected
TBM cases analyzed by ELISA for anti-TB antibodies, 111
(46.25%) cases showed antibody positivity (Table 2). The
remaining 129 CSF samples categorized as chronic meningitis
were found to be negative for anti-tuberculous antibodies by
ELISA. Thirty CSF samples which were categorized as
infectious non-tuberculous meningitis and another 30 CSF
samples of non-diseased category were all negative for
anti-mycobacterial antibodies by ELISA.
Western blot reactivity of TBM-suspected CSF samples
(n = 240) with MTSE antigen showed 81 cases (33.75%) positive
by the assay. The molecular mass of the visible band was cal-
culated by the standard protein marker. The CSF reactivity
was mainly noticed in the region of 30–40 kD followed by
Fig. 1B – Western blot reactivity of monoclonal antibodies to
M. tuberculosis antigens. Lane 1. M. tuberculosis specific
monoclonal antibody (TB-72) against 38 kD protein. Lane 2.
M. tuberculosis quasi specific antibody (TB-68) against 14 kD
antigen of M. tuberculosis. Lane 3. Monoclonal antibody (ML-
34) against mycobacterial common lipoarabinomannan at
30–40 kD region. Lane 4. Anti BCG antibody (polyclonal)
reactivity with M. tuberculosis. Lane 5. Molecular weight
markers.
Table 2 – Comparison of anti-mycobacterial antibody response in CSF samples by ELISA and Western blotting (WB).





TBM suspected (N-240) 111/240 (46.25) 81/240 (33.75) 30–40 kD
Infectious cases other than TBM (N-30) 0/30 (0) 0/30 (0) None
Non-infectious cases (N-30) 0/30 (0) 0/30 (0) None
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 1 2 4 –1 3 0 12714 kD region (Fig. 1A). The remaining 159 CSF samples sus-
pected for TBMwere found to be non-reactive to MTB antigen.
Among the non-tuberculous meningitis CSF samples (n = 30)
and non-diseased CSF controls (n = 30), none showed reactiv-
ity by Western blot. Western blot reactivity using monoclonal
antibodies against lipoarabinomannan (30–40 kD) and 14 kD
region revealed strong reactivity to these antigens. However,
the reactivity to the 38 kD region by MTB-specific monoclonal
antibody TB-72 revealed weak reactivity (Fig. 1B). Comparison
of ELISAwith Western blotting revealed higher antibody posi-
tivity in ELISA compared with Western blotting. It is noticed
that 76 CSF of suspected TBM were found to be positive by
both ELISA and Western blot for anti-mycobacterial antibody.
Five CSF samples suspected as TBM which were found to be
borderline positive for anti-mycobacterial antibody by ELISA
with the OD between 0.1 and 0.13 were shown reacting by
Western blot with prominent band at the 30–40 kD region.
Among the 5 samples, 1 was showing reactivity to both the
30–40 kD and 14 kD regions.
Western blot analysis of CSF from clinically confirmed
and/or suspected TBM patients revealed a major antibody
against mycobacterial antigen with a mass in the 30–40 kD
region which corresponds to lipoarabinomannan antigen
which is noticed to be highly immunogenic.
In the highly probable category (n = 53), 80% of the CSF
were positive by ELISA and 62% by Western blot. Among the
probable cases (n = 85), 50% of the CSF were positive by
ELISA and 37% by Western blot. In the possible TBM cases
(n = 102), 25% and 17% were positive by ELISA and Western
blot, respectively (Table 3).Fig. 1A – Lane 1–16. Western blot analysis for suspected TBM CSF samples (n = 16), showing reactivity at 30–40 kD and 14 kD
region.
Table 3 – Category wise comparison of ELISA positivity and Western blot reactivity.
Category No. of patients Antibody positivity
ELISA (%) Western blot (%)
Highly probable 53 42 (80) 33 (62)
Probable 85 43 (50) 31 (37)
Possible 102 26 (25) 17 (17)
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TBM is a serious form of TB with high morbidity and mortal-
ity. To contain the disease, early diagnosis and effective treat-
ment is essential. The routinely practiced diagnostic
techniques include isolation and staining of the causative
organism MTB in the clinical specimen. The culture tech-
nique, though robust and the gold standard, is less sensitive
in CSF and may not help in early diagnosis. According to
previous reports from this center, the organism from the
CSF could be isolated to the extent of about 15% in the TBM
cases in spite of best efforts [12].
Biochemical analysis of CSF in TBM for measuring glucose
and protein levels as an indirect indicator of the infection
lacks specificity for CNS-TB [22]. Elevated CSF Adenosine
deaminase (ADA) activity has been observed in patients with
tuberculous effusions. However, it has a low sensitivity (44%),
and ADA analysis cannot differentiate TB infection from
other bacterial infections [23]. Interferon gamma release
assay is another technique in which interferon gamma will
be released by the immune cells after stimulation by myco-
bacterial antigens which can be measured and compared
with controls for the diagnosis [24]. However, this test does
not effectively distinguish between the present and the past
infection. PCR, another molecular technique, is found to be
less satisfactory in CSF samples due to low bacillary load
and also due to PCR amplification inhibitory components
noticed in occasional CSF samples [25]. A recent report by
Jongeling and Pisapia [26] revealed the late appearance of
molecular markers in TBM which led to the delay in the treat-
ment and ultimately the death of a patient. Hence, there is an
urgent need for the rapid diagnostic confirmation of this ser-
ious disease. As antibody response to the antigens in CSF will
be much quicker compared with the detection of other bio-
markers, the antibody response would be a promising early
indicator.
Human immune response to MTB varies from individual to
individual and population to population and antigen to anti-
gen. In view of this, various workers have used multiple
mycobacterial antigens as TB diagnostic markers [27,28].
Cell-mediated immune response also varies with different
antigens of MTB in TB patients [29]. In the present study,
the total MTSE extract was used as the antigen to have multi-
ple antigenic epitopes for the test in both ELISA and Western
blot. Usefulness of the mycobacterial strain H37Ra in prepara-
tion of the antigen of diagnostic significance in TB is well
established in many laboratories [30]. The present study also
reports the use of H37Ra sonicate antigen for the diagnosisof TBM byWestern blot. In one of the earlier preliminary stud-
ies, the Western blot procedure with H37Rv sonicate antigen
was reported [18], and that a vast majority of the proteins
were similar in both the strains of MTB (H37Ra and H37Rv).
These strains are very close biochemically [31], except that
the H37Rv is virulent and may contribute to handling
complications.
These results using monoclonal antibodies reveal that
the antibody responses are induced to multiple MTB anti-
gens, including the highly immunodominant lipoarabino-
mannan (30–40 kD). Increased reactivity to 30–40 kD
components is also reported in the closely related myco-
bacterial infection, leprosy [32]. The immunogenic nature
of LAM is also reported in TBM [18], and also in the sera
of pulmonary TB cases [33,34] and in leprosy [35]. This
indicates that the lipoarabinomannan molecule is highly
immunogenic in CSF as well as in serum. Further, the anti-
body response to this polysaccharide antigen is noticed to
be disease specific.
It is observed in the present study that few of the CSF sam-
ples which were antibody positive by ELISAwere non-reactive
on Western blot. This could be due to some degree of non-
specificity in ELISA. Further, five of the CSF samples which
were marginally positive (borderline positive) by ELISA
showed reactivity by Western blot, highlighting appropriate
reactivity to the presence of antibodies with reasonable
sensitivity.
The comparison of both ELISA and Western blot in the
present study has highlighted the specific binding in Western
blotting, which can be used as an immunoconfirmatory test
for TBM. Some degree of non-specificity in ELISA could be
attributed to the non-specific binding components in CSF
which bind passively to the ELISA plate. Such CSF samples
when tested do show non-specific reactivity to any antigen
coated or even to a blank ELISA plate itself.
The comparison of ELISA and Western blotting done in the
present study signifies the evaluation of the definitive
antibody response by Western blotting, whereas in ELISA
there is likely to be nonspecific reactions. The present study
is the largest in the series to report the comparison of
ELISA with Western blot in the CSF of TBM cases. The
predominant reactivity to the lipoarabinomannan and 14 kD
protein of MTB in CSF needs to be strongly considered while
developing any new diagnostic tests for TBM. Further,
whenever the clinical suspicion is not strong for TBM and
there is antibody positivity by ELISA, it is recommended that
Western blot be done for confirming the infection by ruling
out the ambiguity.
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